Pioglitazone and Lower Risk of Dementia

This publication has 10 references indexed in Scilit:

• Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke
  Neurology, 2023
• Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
  Diabetes Care, 2022
• Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators
  Pharmacoepidemiology and Drug Safety, 2022
• IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
  Diabetes Research and Clinical Practice, 2022
• Association Between Age at Diabetes Onset and Subsequent Risk of Dementia
  JAMA, 2021
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
  Canadian Journal of Diabetes, 2020
• A population‐based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns
  Pharmacoepidemiology and Drug Safety, 2019
• Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis
  BMJ Open Diabetes Research & Care, 2018
• Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
  Nature Reviews Endocrinology, 2018
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  The Lancet, 2005